Related Experiment Video
Updated: Apr 13, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma
Hiroaki Kanemura1, Hidetoshi Hayashi1
1Department of Medical Oncology, Kindai University Faculty of Medicine, 1-14-1 Mihara-dai, Minami-ku, Sakai, Osaka 590-0197, Japan.
Abstract:
MRG003, a novel EGFR-targeted antibody-drug conjugate (ADC), demonstrates significant efficacy in heavily pretreated patients with recurrent or metastatic nasopharyngeal carcinoma. With an objective response rate of 42% and encouraging overall survival, MRG003 appears to overcome previous limitations of EGFR therapies. Its manageable safety profile and bystander-killing effect highlight the potential of ADCs to revolutionize treatment paradigms in this population.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Mitogens and the Cell Cycle
Tumor Immunotherapy
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists